Home Blog Page 5584

Aventis Learning Group To Hold Phygital Metaverse Event

By
Laotian Times
-
SINGAPORE – Media OutReach – 7 June 2022 – Aventis Learning Group is excited to announce its first phygital event, “Getting Into The Metaverse and Web3 – The Next Frontier,” on 30th June 2022. The event will be available live on 3 different modes – physically at Concorde Hotel Singapore, virtually through Zoom and digitally on Metaverse via Decentraland.

Scheduled on 30th June 2022, from 9am to 5pm, this 1-day professional development course explores how the metaverse can unlock opportunities for businesses. By the end of this digital transformation course, participants will gain a deeper understanding of phygital business models, how the metaverse works, and how to leverage digital assets to grow their company.

The CEO and Founder of IKIGUIDE Metaverse Collective, Ms Soh Wan Wei will be speaking at this event. Ms Soh is a local tech futurist and thought leader in the metaverse and Web 3.0 space. A well sought-after speaker, she has presented at over 50 prominent blockchain and artificial intelligence industry conferences across the world, including the Blockchain Summit Singapore in 2019.

The metaverse economy is growing at a rapid speed, with reputable brands such as Adidas, JP Morgan, and Samsung purchasing virtual real estate in the metaverse in recent months. Moreover, a recent report by Citibank has forecasted that the metaverse could be worth $13 trillion by 2030. Hence, it is beneficial for working professionals to learn how to tap on the metaverse to transform and grow their businesses.

Mr Samuel Teo, General Manager of Aventis Learning Group said, “We are extremely excited about this event. As the pioneer in our first-ever tri-dimensional event, this first-of-its-kind metaverse event showcases the immersive metaverse experience brands can leverage on to grow their presence and enhance their customers’ experience.”

“At Aventis, we celebrate that the metaverse is upon us and that it will help us democratise executive education across ASEAN, which has a growing population of over 700 million. The metaverse will be omnipresent and with rapid technological advancements, able to bring us new immersive learning experiences. Aventis’ metaverse offers a hybrid world of enormous potential. We, as educators, play an important role to ensure the building of a collaborative, positive, and safe learning environment for all our learners. The metaverse is not a direct replacement for face-to-face classes, rather, it is complementary and adds an exciting new dimension to our existing learning model. The Phygital approach will also put us in good stead to allow our learners and alumni to learn, grow, and connect with like-minded professionals and senior executives across ASEAN. Lastly, our Learn-to-Earn model will encourage learners and corporate sponsors to work together and foster a self-sustainable community and ecosystem across ASEAN,” said Mr Teo.

About Aventis Learning Group

Aventis Learning Group is a multi-award-winning provider of online courses in Singapore. Established in 2008, the organisation is a corporate training solutions provider that offers cutting-edge professional courses and solutions for working professionals to keep up with evolving industry trends. Their upcoming “Getting Into the Metaverse and Web3 – The Next Frontier” course is priced at $350 – exclusive of GST and inclusive of an e-certificate and learning materials.

For more information and to browse the various courses offered by Aventis Learning Group, please visit . Alternatively, please contact Ms Chye Fen at or 6720 3333.

#AventisLearningGroup

OPPO upgrades its Premium Service with the launch of Find X5 Series

By
Laotian Times
-
SHENZHEN, CHINA – Media OutReach – 7 June 2022 – Prioritizing user experiences has always been essential to successful customer relationships. Since 2021, OPPO has put more effort into enhancing its high-end service capacity overseas such as introducing new services in its existing Premium Service. OPPO Premium Service consists of International Warranty, Exclusive Hotline, Premium Lane with Exclusive Engineers, Loan Phone, Send-in Repair and their latest addition – Door-to-door Repair Collection Service now, but the specific offer may vary by region.

Caption

Accessible and convenient service is paramount to many users and OPPO recognizes that. The new Door-to-door Repair Collection Service is the latest premium service that OPPO has to offer. One just simply needs to contact the local service center to enjoy free pick-up and delivery services. This perk is valid twice within the first year for Find X5 Pro 5G users, but the specific service policy might vary per market. As this exclusive option is in the pilot phase, it is only available at certain places in Malaysia, Thailand, and Indonesia.

While the new Door-to-door Repair Collection Service is limited to certain areas, OPPO also provides a Send-in Repair Service for users who are located at places that are not covered, allowing users to send in their phones to OPPO service centers and no courier fees are required in some countries and regions.

Besides the above, OPPO has also improved personnel training courses and built a specialist team of ‘Find Masters’, a group of high-level engineers and online consultants exclusively for Find series customers to further upgrade customer experience at its service centers.

OPPO is truly making it possible to provide customers with not just an excellent device but also an enjoyable, distinctive experience and a satisfactory repair service under the service motto, “Care & Reach”.

For more information on OPPO Premium Service for Find X5 Series, kindly refer to: https://support.oppo.com/en/premium-service-findx5-series/

X0PA Partners with Meta, TTC Labs and IMDA For People-centric Approaches to Algorithmic Explainability Project

By
Laotian Times
-
SINGAPORE – Media OutReach – 7 June 2022 – X0PA AI is one of the five start-ups in the Asia Pacific and Europe, chosen by TTC Labs, Meta, and IMDA to collaborate to engage start-ups and policymakers on prototyping policies and products that focus on AI explainability.

With the increasing adoption of AI across various industry verticals and use cases, the conversations around greater transparency and explainability of AI systems are also growing. The overall AI ecosystem is looking to foster trust in AI. Globally, several principles, guidelines, frameworks, and laws have been created to govern the development and use of AI. Singapore has published a Model AI Governance Framework (Model Framework) which advocates transparency and explainability in the decisions made by, or with, the assistance of AI.

The Model Framework and the associated guide, the Implementation and Self-Assessment Guide for Organisations (ISAGO), provide practical tools to help developers and users of AI systems do this responsibly. To ensure the implementation of this framework and guide, the Infocomm Media Development Authority of Singapore (IMDA) partnered with Meta’s TTC Labs and Open Loop to translate key concepts of transparency and explainability into prototypes.

X0PA amongst other four startups was chosen to test the product framework for AI explainability, build prototypes, and share their findings, insights, and experiences.

“X0PA participated so we get to work together with other start-ups, Meta, TTC Labs and IMDA to further improve our product development prototyping process so that we can make our AI more explainable and provide a better user experience. We also participated as we strongly believe in working together to push for a people-centric and explainable approach to AI,” says Lee Gang, Head of Data Science, X0PA AI.

The objectives of this project were to

  • Build AI transparency principles into an operational AI explainability and control (AIX) framework. This framework will provide guidance for front-end experiences across industry use cases.
  • Understand future-facing challenges and best practices to help inform industry-facing public policy developments showcasing what ideal governance paths might look like.
  • Produce report synthesizing research process, outputs, and learnings into practical insights.

Check out the insights and learnings in the report, click here

About X0PA AI

X0PA is an AI-powered end-to-end B2B platform that helps in streamlining hiring and selections, from sourcing potential candidates, screening objectively and at scale, virtual and asynchronous interview/assessments, and final selections and onboarding. The sophisticated built-in automation helps in scaling efficiencies multi-fold, however, the biggest advantage of X0PA is the power of objectivity in selections.

Using AI and ML to “screen candidates in rather than screen out” by eliminating biases both from humans as well as from the process that truly helps in making hiring equitable.

Recognized by IDC as AI-Innovator of APAC, X0PA has additionally won many other accolades and awards.

Want to know more about X0PA’s AI Recruitment Platform?

#X0PA

Chubb launches Individual Personal Accident and Group Personal Accident & Critical Illness Plans in Hong Kong SAR

By
Laotian Times
-
HONG KONG SAR – Media OutReach – 7 June 2022 – Chubb announced the launch of two new insurance plans: My Accident Guard for individuals and Enterprise Employees Accident & Illness Benefits for small-medium business enterprises (SMEs) in Hong Kong SAR.

My Accident Guard

A market-leading insurance plan, My Accident Guard covers individuals in occupations of manual work or hazardous nature and those participating in non-racing sports activities. The coverages include death and disability benefits of up to HKD2.5 million, medical expenses and hospital cash due to infectious diseases and/or bodily injury. Customers also have an option to add a weekly income benefit which is paid if the customer is certified by a doctor for temporarily being unable to carry out his usual work. Applicants can easily enroll for the plan by indicating whether their previous accident insurance applications had been refused or insured on special terms, without the need for prior medical check-up or declaration of salary.

Highlights of this product include1 :
1. Personal accident and permanent total disablement benefits of up to HKD2.5 million.
2. Medical expenses for infectious diseases and/or bodily injury up to HKD25,000 – no sub-limit for surgery, chiropractor, physiotherapist or x-ray.
3. Hospital cash for infectious diseases and/or bodily injury up to HKD500 per day.
4. Fracture bones (including hairline fracture) up to HKD30,000.
5. 24-hour worldwide coverage.

Enterprise Employees Accident & Illness Benefits Plan

The Enterprise Employees Accident & Illness Benefits Plan is an all-in-one policy combining personal accident, accidental medical expenses, critical illness and compassionate death coverages. With pre-set benefit levels, it is easier for employers to calculate the premium costs of covering their most valuable assets – the employees.

Highlights of this product include1:
1. Combining personal accident and critical illness in one policy.
2. Unisex premium.
3. Provision of employee coverages on unnamed basis.
4. No medical check-up required / no medical questionnaire.
5. 24-hour worldwide coverage.

Scott Simpson, President of Chubb’s general insurance business in Hong Kong and Macau said, “As a global leader in personal accident and supplemental health insurance, Chubb understands that injuries will be a financial burden for individuals and employers, especially for SMEs. We are thrilled to launch these two new plans with market-leading benefits that satisfy the needs of individuals and SMEs. They will be pleased with the very simple application procedure which reduces time spent on administrative work for employers.”

For more information about Chubb’s My Accident Guard, please visit chubb.com/hk-en/personal/my-accident-guard.

For more information about Chubb’s Enterprise Employees Accident & Illness Benefits Plan, please visit chubb.com/hk-en/business/enterprise-employees-accident-and-illness-benefits.

Disclaimer: The above information is not intended to illustrate nor represent the coverages, services and service levels offered by Chubb. Please review the full terms, conditions and exclusions of the relevant policy(ies) and consider whether the advice is right for you.

1 These product highlights are an overview of the key features of the product. Please see the actual policy for exact terms, conditions and exclusions.

About Chubb

Chubb is the world’s largest publicly traded property and casualty insurance company. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. As an underwriting company, we assess, assume and manage risk with insight and discipline. We service and pay our claims fairly and promptly. The company is also defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb maintains executive offices in Zurich, New York, London, Paris and other locations, and employs more than 30,000 people worldwide.

With both general and life insurance operations, Chubb has been present in Hong Kong SAR for more than 90 years via acquisitions by its predecessor companies. Its general insurance operation in Hong Kong SAR (Chubb Insurance Hong Kong Limited) is a niche and specialist general insurer offering products such as property, casualty, marine, financial lines and consumer lines designed for large corporates, midsized commercial & small business enterprises as well as retail customers. The AA- long term insurer financial strength and counterparty credit ratings by Standard & Poor’s are indicative of the company’s strong capitalisation. Over the years, the company has built strong client relationships by being consistent and responsive, by offering market leading claims services and innovative products, and providing market leadership built on financial strength.

More information can be found at: www.chubb.com/hk.

#Chubb

UFC® to Make History in Singapore with UFC® 275: TEIXEIRA vs PROCHAZKA

By
Laotian Times
-
SINGAPORE – Media OutReach – 7 June 2022 – UFC® returns to Singapore with Southeast Asia’s first-ever Pay-Per-View event UFC® 275: TEIXEIRA vs PROCHAZKA on June 11 (live in Singapore on June 12) featuring the first UFC championship bouts to take place in the region. This historic event will be UFC’s fourth event hosted in Singapore with support from the Singapore Tourism Board.

UFC-275-header-ASIA.jpeg

UFC LIGHT HEAVYWEIGHT CHAMPIONSHIP

In the ultra-competitive light heavyweight division, UFC champion Glover Teixeira will make his first title defense since winning the belt with a second-round submission of Jan Blachowicz at UFC 267. Standing across the Octagon® will be first-time title contender Jiri Prochazka who earned his shot with back-to-back KOs of Volkan Oezdemir in his UFC debut and later Dominick Reyes.

UFC WOMEN’S FLYWEIGHT CHAMPIONSHIP

Women’s pound-for-pound best, UFC women’s flyweight champion Valentina Shevchenko will make her seventh title defense and look to extend her eight-fight win streak. Dana White’s Contender Series veteran and No. 4 contender Taila Santos earns her first title contention after a blazing four-fight win streak.

2020 FIGHT OF THE YEAR REMATCH

China’s first UFC world champion, No. 1 ranked strawweight Zhang Weili, will rematch former UFC world strawweight champion Joanna Jedrzejczyk. This contender’s bout in the ultra-competitive strawweight division is a highly anticipated rematch of their first encounter in 2020 that was awarded Fight of the Year.

Additional bouts on the card include:

  • Flyweight: Rogerio Bontorin vs Manel Kape
  • Welterweight: Jack Della Maddalena vs Ramazan Emeev
  • Featherweight: Seungwoo Choi vs Josh Culibao
  • Middleweight: Brendan Allen vs Jacob Malkoun
  • Featherweight: Maheshate vs Steve Garcia
  • Welterweight: Andre Fialho vs Jake Matthews
  • Bantamweight: Kyung Ho Kang vs Batgerel Danaa
  • Women’s Strawweight: Liang Na vs Silvana Gomez Juarez
  • Welterweight: Orion Cosce vs Blood Diamond
  • Women’s Bantamweight: Ramona Pascual vs Joselyn Edwards

A thrilling Fight Week of action builds up to the event which includes the start of ROAD TO UFC, the most significant opportunity for Asia’s top MMA prospects. ROAD TO UFC is a ground-breaking “win and advance” tournament for 32 mixed martial arts athletes who will compete in four men’s weight classes, and each of the four division’s winners will be awarded a UFC contract. The opening round will take place across two days during Fight week for UFC 275 in the Octagon at the Singapore Indoor Stadium. The semifinals and finals are scheduled for later this year.

UFC 275 FIGHT WEEK SCHEDULE

All dates Singapore

  • June 9: ROAD TO UFC, Episodes 1 & 2
  • June 10: ROAD TO UFC, Episodes 3 & 4
  • June 10: UFC 275 Weigh Ins
  • June 12: UFC® 275: TEXEIRA vs PROCHAZKA

For event updates to UFC® 275: TEXEIRA vs PROCHAZKA, check UFC.com. Tickets are available at Ticketmaster.sg. Check local listings for broadcast.

Follow the latest UFC news on Facebook (UFC), Twitter and Instagram (@ufc), and use the official hashtags: #UFC275 #UFCSINGAPORE.

#UFC

Thailand to Accept Over 160,000 Migrant Workers

By
Laotian Times
-
Migrant workers from Laos, Cambodia and Myanmar in Thailand.

Thailand plans to employ more than 160,000 migrant workers to reduce the number of illegal workers entering the country without quarantine. 

Continue

US Deputy Secretary of State to Visit Laos

By
Laotian Times
-

US Deputy Secretary of State Wendy Sherman will travel to the Republic of Korea (ROK), the Philippines, Vietnam, and Laos from 5 June to 14 June.

Continue

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

By
Laotian Times
-
BEIJING, CHINA – Media OutReach – 6 June 2022 – Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

The financing comprised a mix of new investors, including a large, diversified asset management firm on the US West Coast and BHR Partners, along with current investors, including Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. Insilico’s founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.

Capital raised in the round will further bolster Insilico’s financial position and fuel the growth of its advancing pipeline, including its lead program which is currently in a Phase I study, and continued development of its Pharma.AI platform. The proceeds will also fund ongoing global expansion and planned strategic initiatives, including a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement Insilico’s vast curated data assets.

“Despite unprecedented market conditions in the biotechnology sector, we raised this Series D round from several of the most reputable US-based and global investors,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “It is a testament to the strength of our end-to-end AI platform, which has been validated by many partners, and produced our first novel antifibrotic program discovered using AI and aging research, and designed using our generative AI chemistry engine. This unique program completed a first-in-human Phase 0 study in healthy volunteers and has entered Phase I clinical trials. We have also nominated seven preclinical candidates across a number of other disease indications since 2021. I am very excited about this progress and have decided to personally invest in this round.”

“The application of artificial intelligence and machine learning for drug discovery has incredible potential to transform the way new therapies are developed,” said Min Fang, Managing Director, Head of China Healthcare at Warburg Pincus. “For Insilico, 2022 was a year of incredible growth and progress. They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery. We’re delighted to continue to partner with the Insilico team and support a company that is at the forefront of this innovation.”

Since the previous round of financing, Insilico has developed a growing portfolio in frontier areas empowered by its proprietary AI platform. Seven programs in its internal pipeline have progressed to the IND-enabling stage, including a novel 3CL protease inhibitor for COVID-19 treatment, and two synthetic lethality programs targeting MAT2A and USP1 for oncology. It also successfully completed a Phase 0 microdose study and entered a Phase I clinical trial with its first internally developed program targeting fibrosis.

“With the power of cutting-edge AI platforms developed fully in house and validated by many global pharmaceutical companies and our innovative, highly parallel, fully distributed drug discovery model, we nominated seven preclinical candidates since I joined the company in 2021,” said Feng Ren, PhD, Insilico’s Chief Scientific Officer and Head of Global Research and Development. “I have 15 years of experience working in large pharmaceutical companies and CROs and I am impressed by the speed and quality of our discovery programs. We plan to continue expanding the breadth of the pipeline and enhance our AI and robotics capabilities globally. Our rapidly growing team is composed of talented and experienced scientists in drug discovery with diverse backgrounds and relentless passion for novelty and innovation, and fully committed to developing novel drugs with a sense of urgency for the waiting patients.”

Insilico has also expanded its collaborations with the pharmaceutical industry through co-development and software licensing deals with a number of major pharmaceutical companies. Since the launch of its PandaOmics™ and Chemistry42™ in late 2020, nine out of the top 20 pharmaceutical companies have licensed Insilico’s AI platforms. In 2022, Insilico signed a multi-asset partnership deal with Fosun Pharma and EQRX in January, and a drug discovery co-development deal with EQRx in March. Notably, Insilico achieved its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy in less than 40 days into the strategic collaboration with Fosun Pharma.

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

#InsilicoMedicine #BCapitalGroup

1...5,5835,5845,585...6,569Page 5,584 of 6,569